Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 416

1.

Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats.

Knoll AT, Meloni EG, Thomas JB, Carroll FI, Carlezon WA Jr.

J Pharmacol Exp Ther. 2007 Dec;323(3):838-45. Epub 2007 Sep 6.

2.

Infralimbic kappa opioid and muscarinic M1 receptor interactions in the concurrent modulation of anxiety and memory.

Wall PM, Messier C.

Psychopharmacology (Berl). 2002 Mar;160(3):233-44. Epub 2002 Jan 31.

PMID:
11889492
3.

Protein synthesis and the mechanisms of lasting change in anxiety induced by severe stress.

Adamec R, Strasser K, Blundell J, Burton P, McKay DW.

Behav Brain Res. 2006 Feb 28;167(2):270-86. Epub 2005 Oct 26.

PMID:
16256211
5.

Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.

Thomas JB, Atkinson RN, Vinson NA, Catanzaro JL, Perretta CL, Fix SE, Mascarella SW, Rothman RB, Xu H, Dersch CM, Cantrell BE, Zimmerman DM, Carroll FI.

J Med Chem. 2003 Jul 3;46(14):3127-37.

PMID:
12825951
6.

Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats.

Knoll AT, Muschamp JW, Sillivan SE, Ferguson D, Dietz DM, Meloni EG, Carroll FI, Nestler EJ, Konradi C, Carlezon WA Jr.

Biol Psychiatry. 2011 Sep 1;70(5):425-33. doi: 10.1016/j.biopsych.2011.03.017. Epub 2011 Apr 30.

7.

LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.

Rorick-Kehn LM, Witkin JM, Statnick MA, Eberle EL, McKinzie JH, Kahl SD, Forster BM, Wong CJ, Li X, Crile RS, Shaw DB, Sahr AE, Adams BL, Quimby SJ, Diaz N, Jimenez A, Pedregal C, Mitch CH, Knopp KL, Anderson WH, Cramer JW, McKinzie DL.

Neuropharmacology. 2014 Feb;77:131-44. doi: 10.1016/j.neuropharm.2013.09.021. Epub 2013 Sep 23.

PMID:
24071566
8.

Favoured genetic background for testing anxiolytics in the fear-potentiated and light-enhanced startle paradigms in the rat.

Steiner MA, Lecourt H, Rakotoariniaina A, Jenck F.

Behav Brain Res. 2011 Aug 1;221(1):34-42. doi: 10.1016/j.bbr.2011.02.021. Epub 2011 Feb 24.

PMID:
21354212
9.

Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice.

Bourin M, Nic Dhonnchadha BA, Claude Colombel M, Dib M, Hascoët M.

Behav Brain Res. 2001 Sep 28;124(1):87-95.

PMID:
11423169
10.
11.

Cannabinoid CB1 receptors of the rat central amygdala mediate anxiety-like behavior: interaction with the opioid system.

Zarrindast MR, Sarahroodi S, Arzi A, Khodayar MJ, Taheri-Shalmani S, Rezayof A.

Behav Pharmacol. 2008 Oct;19(7):716-23. doi: 10.1097/FBP.0b013e3283123c83.

PMID:
18797248
12.

Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist.

Carroll I, Thomas JB, Dykstra LA, Granger AL, Allen RM, Howard JL, Pollard GT, Aceto MD, Harris LS.

Eur J Pharmacol. 2004 Oct 6;501(1-3):111-9.

PMID:
15464069
13.

Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats.

Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens WC Jr, Jones RM, Portoghese PS, Carlezon WA Jr.

J Pharmacol Exp Ther. 2003 Apr;305(1):323-30.

14.

Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats.

Pietraszek M, Sukhanov I, Maciejak P, Szyndler J, Gravius A, Wisłowska A, Płaźnik A, Bespalov AY, Danysz W.

Eur J Pharmacol. 2005 May 2;514(1):25-34. Epub 2005 Apr 19.

PMID:
15878321
15.

Anxiogenic treatments do not increase fear-potentiated startle in mice.

Risbrough VB, Geyer MA.

Biol Psychiatry. 2005 Jan 1;57(1):33-43.

PMID:
15607298
16.

A comparative study with two types of elevated plus-maze (transparent vs. opaque walls) on the anxiolytic effects of midazolam, one-trial tolerance and fear-induced analgesia.

Albrechet-Souza L, Oliveira AR, De Luca MC, Tomazini FM, Santos NR, Brandão ML.

Prog Neuropsychopharmacol Biol Psychiatry. 2005 May;29(4):571-9. Epub 2005 Mar 5.

PMID:
15866360
17.

Identification of short-acting κ-opioid receptor antagonists with anxiolytic-like activity.

Peters MF, Zacco A, Gordon J, Maciag CM, Litwin LC, Thompson C, Schroeder P, Sygowski LA, Piser TM, Brugel TA.

Eur J Pharmacol. 2011 Jul 1;661(1-3):27-34. doi: 10.1016/j.ejphar.2011.04.017. Epub 2011 Apr 27.

PMID:
21539838
18.

The brain orexin system and almorexant in fear-conditioned startle reactions in the rat.

Steiner MA, Lecourt H, Jenck F.

Psychopharmacology (Berl). 2012 Oct;223(4):465-75. Epub 2012 May 17.

PMID:
22592903
19.

The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510).

Varty GB, Lu SX, Morgan CA, Cohen-Williams ME, Hodgson RA, Smith-Torhan A, Zhang H, Fawzi AB, Graziano MP, Ho GD, Matasi J, Tulshian D, Coffin VL, Carey GJ.

J Pharmacol Exp Ther. 2008 Aug;326(2):672-82. doi: 10.1124/jpet.108.136937. Epub 2008 May 20.

20.

Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents.

Saitoh A, Kimura Y, Suzuki T, Kawai K, Nagase H, Kamei J.

J Pharmacol Sci. 2004 Jul;95(3):374-80.

Supplemental Content

Support Center